We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Nanoparticle Treatment Cures Bacterial Infection in Model

By LabMedica International staff writers
Posted on 24 Jul 2017
A novel approach for treating bacterial infections is based on the use of porous silicon nanoparticles to transport a combination of bactericidal peptides, which penetrate the cell membranes of Gram-negative bacteria and kill them with minimal unpleasant side effects.

In order to improve antibacterial delivery, investigators at the Massachusetts Institute of Technology (Cambridge, MA, USA) developed an anti-infective nanomaterial that utilized two strategies for localization: i) a biodegradable nanoparticle carrier to localize therapeutics within the tissue, and ii) a novel tandem peptide cargo to localize payload to bacterial membranes.

The first step was to screen a library of antibacterial peptides that combined membrane-localizing peptides with toxic peptides. More...
This screen identified a tandem peptide - the toxic peptide KLAKAK (lysine-leucine-alanine-lysine-alanine-lysine) and the transport peptide lactoferrin - that displayed synergy between the two domains and was able to kill Pseudomonas aeruginosa at sub-micromolar concentrations.

To apply this material to the lung, the tandem peptide was loaded into porous silicon nanoparticles (pSiNPs). Charged peptide payloads were loaded into the pores of the pSiNP at approximately 30% mass loading and approximately 90% loading efficiency using phosphonate surface chemistry.

The investigators reported in the July 12, 2017, online edition of the journal Advanced Materials that when delivered to the lungs of mice, this anti-infective nanomaterial was 30 times more effective at killing Pseudomonas aeruginosa than were the individual peptides administered without a carrier, and it was less toxic than the free peptides. Moreover, treatment of a lung infection of P. aeruginosa resulted in a large reduction in bacterial numbers and markedly improved survival compared to untreated mice.

This approach is modeled on a strategy that the investigators had previously used to deliver targeted cancer drugs. "There are a lot of similarities in the delivery challenges," said senior author Dr. Sangeeta Bhatia, professor of health sciences, technology and electrical engineering, and computer science at the Massachusetts Institute of Technology. "In infection, as in cancer, the name of the game is selectively killing something, using a drug that has potential side effects. We have adapted a lot of the same concepts from our cancer work, including boosting local concentration of the cargo and then making the cargo selectively interact with the target, which is now bacteria instead of a tumor."

Related Links:
Massachusetts Institute of Technology


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.